Progress: Procedure completed
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | ENVI | LA VIA Giovanni ( PPE) | BORZAN Biljana ( S&D), KRUPA Urszula ( ECR), RIES Frédérique ( ALDE), AUKEN Margrete ( Verts/ALE), PEDICINI Piernicola ( EFDD), MÉLIN Joëlle ( ENF) |
Committee Opinion | AFCO | BRESSO Mercedes ( S&D) | Elmar BROK ( PPE), Morten MESSERSCHMIDT ( ECR), Jasenko SELIMOVIC ( ALDE) |
Committee Opinion | AGRI | ||
Committee Opinion | CONT | ||
Committee Opinion | BUDG | ||
Committee Opinion | ITRE |
Lead committee dossier:
Legal Basis:
RoP 59-p4
Legal Basis:
RoP 59-p4Subjects
Events
PURPOSE: to relocate the seat of the European Medicines Agency (EMA) following the notification by the United Kingdom to the European Council of its intention to leave the Union.
LEGISLATIVE ACT: Regulation (EU) 2018/1718 of the European Parliament and of the Council of 14 November 2018 amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency.
CONTENT: this Regulation amends Regulation (EC) No 726/2004 to establish the seat of the European Medicines Agency (EMA) in Amsterdam, the Netherlands .
Following the United Kingdom's notification of its intention to withdraw from the Union, the other 27 Member States, meeting on 20 November 2017 in the margins of the Council, chose Amsterdam, the Netherlands, as the new seat of the European Medicines Agency.
The competent authorities of the Netherlands shall take all necessary measures to ensure that the Agency is able to move to its temporary location no later than 1 January 2019 and that it is able to move to its permanent location no later than 16 November 2019.
They shall submit a written report to the European Parliament and the Council on the progress on the adaptations to the temporary premises and on the construction of the permanent building by 17 February 2019, and every three months thereafter, until the Agency has moved to its permanent location.
ENTRY INTO FORCE: 16.11.2018.
APPLICATION: from 30.3.2019.
The European Parliament adopted by 425 votes to 71 with 56 abstentions a legislative resolution on the proposal for a Regulation of the European Parliament and of the Council amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency (EMA).
The European Parliament’s position adopted at first reading under the ordinary legislative procedure amended the Commission proposal as follows:
Following the United Kingdom's notification on 29 March 2017 of its intention to withdraw from the Union, the other 27 Member States, meeting on 20 November 2017 in the margins of the Council, selected Amsterdam, the Netherlands , as the new seat of the European Medicines Agency (EMA).
Timeline : the amended text specifies that the competent authorities of the Netherlands shall take all necessary measures to ensure that the Agency is able to move to its temporary location no later than 1 January 2019 and that it is able to move to its permanent location no later than 16 November 2019 .
The competent authorities of the Netherlands shall submit a written report to the European Parliament and the Council on the progress on the adaptations to the temporary premises and on the construction of the permanent building by three months after the entry into force of this amending Regulation, and every three months thereafter, until the Agency has moved to its permanent location.
Members regretted the decision of the Council which leads to a deepening of the geographical disproportionality with only 9 out of 37 EU decentralised agencies being located in new Member States contrary to the European Council Conclusions which both give priority to new Member States. They called on the budgetary authorities and the Commission to ensure that the costs relating to the change in the seat of EMA will be fully covered by the current host country.
Parliament’s role : in a statement, Parliament condemned the procedure followed for the selection of the new location of the seat, which has de facto deprived the European Parliament of its prerogatives since it was not effectively involved in the process, but is now expected to simply confirm the selection made for the new location of the seat by means of the ordinary legislative procedure.
The European Parliament wishes to recall as well that in the Inter-institutional Agreement on Better Law-Making of 13 April 2016 the three institutions committed to sincere and transparent cooperation while recalling the equality of both co-legislators as enshrined in the Treaties.
In a statement to the legislative resolution , Parliament recognised the commitment of sincere and transparent cooperation, and in the light of the process followed for the relocation of the EMA and EBA, which was specific to the situation and did not constitute a precedent for location of agencies in the future.
The Council took note of the request by Parliament to revise, as soon as possible, the 2012 Joint Statement and Common Approach on decentralised Agencies. As a first step, it invited the Commission to provide, by April 2019, an in-depth analysis of the implementation of the Joint Statement and Common Approach as regards the location of decentralised Agencies.
The European Parliament adopted by 507 votes to 112, with 37 abstentions, amendments to the proposal for a regulation of the European Parliament and of the Council amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency.
The matter was referred back to the committee responsible for interinstitutional negotiations.
As a reminder, the Commission proposal aims at amending Regulation (EC) No 726/2004 in order to confirm the seat of the European Medicines Agency in Amsterdam, the Netherlands .
The main amendments adopted in plenary concern the following issues:
Precise timeline : Members suggested the Commission and the Dutch authorities shall take all the necessary measures to ensure that the Agency can move to its temporary location no later than 1 January 2019 and that it can move to its permanent location no later than 16 November 2019 .
The Commission and the competent authorities of the Netherlands shall submit a written report to the European Parliament and the Council on the progress on the adjustments of the temporary premises and on the construction of the permanent building three months after the entry into force of this Regulation, and every three months thereafter, until the Agency has moved into its permanent headquarters.
A headquarters agreement allowing the Agency to take up its duties at the premises approved by the European Parliament and the Council shall be concluded within three months from the date this Regulation enters into force.
Respect for the prerogatives of the Parliament : in a statement , the Parliament condemned the procedure followed for the selection of the new location of the seat, which has de facto deprived the European Parliament of its prerogatives since it was not effectively involved in the process, but is now expected to simply confirm the selection made for the new location of the seat by means of the ordinary legislative procedure.
Under these circumstances, Parliament insisted that the procedure followed for the selection of a new location for the agencies will be revised and not used anymore in this form in the future.
Lastly, Parliament wished to recall as well that in the Inter-institutional Agreement of 13 April 2016 on Better Law-Making the three institutions committed to sincere and transparent cooperation while recalling the equality of both co-legislators as enshrined in the Treaties.
The Committee on the Environment, Public Health and Food Safety adopted the report Giovanni LA VIA (EPP, IT) on the proposal for a regulation of the European Parliament and of the Council amending Regulation (EC) No 726/2004 as regards the location of the seat of the European Medicines Agency.
As a reminder, the Commission proposal aims at amending Regulation (EC) No 726/2004 in order to confirm the seat of the European Medicines Agency in Amsterdam, the Netherlands .
The committee recommended that the European Parliament’s position adopted at first reading under the ordinary legislative procedure should amend the Commission proposal as follows.
According to Members, having a precise timeline in the legislation for the signature of the headquarters agreement is required to prevent delays in the HQ agreement's negotiations and thus to support the preparatory activities for the relocation by 30 March 2019. The headquarters agreement shall include the most appropriate terms and conditions for the successful relocation of the European Medicines Agency and its staff members to Amsterdam.
In order to ensure the Agency’s full business continuity, the temporary location in Amsterdam should be provided as of 1 January 2019 and the permanent headquarters of the Agency should be completed by 15 November 2019. The Commission and the Dutch authorities shall take all the necessary measures to ensure that the Agency can move to its temporary location no later than 1 January 2019 and that it can move to its permanent location no later than 16 November 2019 .
A headquarters agreement allowing the Agency to take up its duties at the premises approved by the European Parliament and the Council shall be concluded within three months from the date this Regulation enters into force.
In a statement annexed to this resolution, Parliament regretted that its role of co-legislator has not been duly taken into account since it was not involved in the procedure leading to the selection of the new seat of the European Medicines Agency (EMA). It recalled its prerogatives as co-legislator and insisted on the full respect of the ordinary legislative procedure in relation to the location of bodies and agencies, while insisting that the procedure followed for the selection of a new location for the agencies will be reformed and not used anymore in this form in the future.
PURPOSE: to relocate the seat of the European Medicines Agency (EMA) following the notification by the United Kingdom to the European Council of its intention to leave the Union.
PROPOSED ACT: Regulation of the European Parliament and of the Council.
ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.
BACKGROUND: the European Medicines Agency has been established by Regulation (EEC) No 2309/93, which has been replaced by Regulation (EC) No 726/2004 .
In accordance with the Decision of 29 October 1993 taken by common agreement between the representatives of the governments of the Member States, meeting at Head of State and Government level, on the location of the seats of certain bodies and departments of the European Communities and of Europol, the European Medicines Agency has its seat in London, United Kingdom.
Following the notification by the United Kingdom of its intention to leave the Union , the 27 remaining Member States, in the margins of the General Affairs Council (Article 50), selected Amsterdam, the Netherlands, as the new seat for the European Medicines Agency.
CONTENT: the Commission proposes to amend Regulation (EC) No 726/2004 in order to confirm the new seat of the European Medicines Agency in Amsterdam, the Netherlands.
The Agency should occupy its new seat from the date on which the Treaties cease to apply to the United Kingdom or from 30 March 2019, whichever is the earlier.
It is proposed that the Regulation shall enter into force as a matter of urgency in order to give the Agency sufficient time to relocate.
BUDGETARY IMPLICATION: the relocation of the Agency will have budgetary implications, in particular in view of the costs related to the early termination of its current rental contract in London as a consequence of the withdrawal, the costs related to the move itself and the costs related to the installation in the new premises in Amsterdam.
As set out in the negotiation directives of the Council of 22 May 2017, the United Kingdom should fully cover the specific costs related to the withdrawal process, such as the relocation of the agencies based in the United Kingdom.
Some of the relocation costs (e.g. costs related to the move itself) may have to be pre-financed by the EU budget prior to the final financial settlement. If necessary, the Commission will submit the relevant proposals to the European Parliament and the Council in the framework of the annual budgetary procedure for 2019 and, if necessary, for 2018.
In addition, the costs related to the installation in the new premises will also be presented in the context of the building procedure set out in Article 203 of the Financial Regulation, which requires prior approval from the European Parliament and the Council before contracts related to building projects are concluded. This procedure is expected to be launched as soon as possible (at the latest in early 2018).
Documents
- Commission response to text adopted in plenary: SP(2018)755
- Final act published in Official Journal: Regulation 2018/1718
- Final act published in Official Journal: OJ L 291 16.11.2018, p. 0003
- Draft final act: 00040/2018/LEX
- Decision by Parliament, 1st reading: T8-0427/2018
- Coreper letter confirming interinstitutional agreement: GEDA/A/(2018)008294
- Text agreed during interinstitutional negotiations: PE629.511
- Approval in committee of the text agreed at 1st reading interinstitutional negotiations: PE629.511
- Approval in committee of the text agreed at 1st reading interinstitutional negotiations: GEDA/A/(2018)008294
- Results of vote in Parliament: Results of vote in Parliament
- Decision by Parliament, 1st reading: T8-0086/2018
- Committee report tabled for plenary, 1st reading: A8-0063/2018
- Committee opinion: PE616.913
- Amendments tabled in committee: PE616.891
- Committee draft report: PE615.463
- Economic and Social Committee: opinion, report: CES0004/2018
- Legislative proposal published: COM(2017)0735
- Legislative proposal published: EUR-Lex
- Economic and Social Committee: opinion, report: CES0004/2018
- Committee draft report: PE615.463
- Amendments tabled in committee: PE616.891
- Committee opinion: PE616.913
- Coreper letter confirming interinstitutional agreement: GEDA/A/(2018)008294
- Text agreed during interinstitutional negotiations: PE629.511
- Draft final act: 00040/2018/LEX
- Commission response to text adopted in plenary: SP(2018)755
Activities
Votes
A8-0063/2018 - Giovanni La Via - Am 9=12 15/03/2018 12:14:05.000 #
A8-0063/2018 - Giovanni La Via - Am 14 15/03/2018 12:14:41.000 #
A8-0063/2018 - Giovanni La Via - Am 13 15/03/2018 12:15:06.000 #
A8-0063/2018 - Giovanni La Via - Proposition de la Commission 15/03/2018 12:16:01.000 #
A8-0063/2018 - Giovanni La Via - Am 16 25/10/2018 12:57:37.000 #
A8-0063/2018 - Giovanni La Via - Am 16 #
Amendments | Dossier |
54 |
2017/0328(COD)
2018/01/31
ENVI
51 amendments...
Amendment 1 #
Draft legislative resolution Citation 5 a (new) - Having regard to Article 50(3) of the Treaty on European Union, the European Medicines Agency should take its new seat as from the date on which the Treaties cease to apply to the United Kingdom or from 30 March 2019, whichever is the earlier, provided the new premises are fit and ready for purpose; if not, and to avoid unnecessary further disruption for those involved, allowances should be made for those services of the European Medicines Agency for which offices have not been fully readied to remain based in London until the new premises are ready.
Amendment 10 #
Draft legislative resolution Paragraph 2 2.
Amendment 11 #
Draft legislative resolution Paragraph 2 2. Regrets that the European Parliament - and ultimately the representatives of the Union’s citizens - were not fully involved in the procedure to select the new seat of the European Medicines Agency (EMA), which was eventually concluded by drawing lots, despite it being such an important decision, a method that disregards democratic rules and is ill-advised, given the respective qualities of each application; decisions in relation to the location of bodies and agencies need, and legally should, be taken under the ordinary legislative procedure, fully respecting the European Parliament's prerogatives, whereby the European Parliament and the Council are equal co- legislators;
Amendment 12 #
Draft legislative resolution Paragraph 2 a (new) 2 a. Notes that while expertise will be developed over time, the loss of the UK’s national competent authority, the Medicines and Healthcare products Regulatory Agency (MHRA), to the joint pool of expertise available under the EMA could be detrimental to the scientific approval of medicines for the EU market in the interim. In 2016, the MHRA led 20 per cent of scientific evaluations of new medicines for the EMA.1b _________________ 1bhttp://www.nhsconfed.org/regions-and- eu/nhs-european-office/brexit/brexit- health-alliance/access-to-medicines-and- medical-technologies
Amendment 13 #
Draft legislative resolution Paragraph 2 a (new) 2a. Regrets that the procedure for the selection of the new EMA headquarters was concluded by drawing lots, despite the importance of this decision; considers that a decision of such vital importance for Europe cannot be left to chance and that the European Parliament, as co- legislator, must be involved in the selection of the new EMA headquarters;
Amendment 14 #
Draft legislative resolution Paragraph 2 a (new) 2a. Welcomes the fact that the new location of the EMA is in line with the preferences of its current staff members,1a thereby minimising the loss to the agency of valuable experience, knowledge and expertise;
Amendment 15 #
Draft legislative resolution Paragraph 2 a (new) 2 a. Regrets the decision of the Council which leads to a deepening of the geographical disproportionality with only 9 out of 37 EU decentralised agencies being located in new Member States contrary to the European Council Conclusions 5381/04 and 11018/1/08 which both give priority to new Member States.
Amendment 16 #
Draft legislative resolution Paragraph 2 b (new) 2b. Considers that the details of the two-stage transfer process, entailing operational restrictions during the transition period, were unclear and lacking transparency and that such obfuscation adversely affected the position of the other Member States during consideration of their applications and the procedure for selecting the new EMA headquarters;
Amendment 17 #
Draft legislative resolution Paragraph 2 b (new) 2 b. Regrets that the relocation of the EMA to Amsterdam has meant that the agency has had to temporarily de- prioritise certain activities, such as its work on paediatric medicines and public health issues. This includes its work on anti-microbial resistance and flu pandemics.1a _________________ 1a http://www.ema.europa.eu/docs/en_GB/do cument_library/Other/2017/10/WC500236 755.pdf
Amendment 18 #
Draft legislative resolution Paragraph 3 3.
Amendment 19 #
Draft legislative resolution Paragraph 3 3. Calls on the budgetary authorities and the Commission to ensure that the costs relating to the change in the seat of EMA will be fully covered by the current host country; points out that some of the costs of the relocation from the current location may have to be pre-financed by the EU budget, prior to the financial settlement with the current host country;
Amendment 2 #
Draft legislative resolution Citation 5 a (new) - whereas decisions regarding the establishment of decentralised EU agencies cannot taken on a random basis but only and exclusively by a democratic process based on measurable criteria of merit;
Amendment 20 #
Draft legislative resolution Paragraph 3 3. Calls on the budgetary authorities and the Commission to ensure that the costs relating to the change in the seat of EMA will be fully covered by the
Amendment 21 #
Draft legislative resolution Paragraph 3 3. Calls on the budgetary authorities and the Commission to ensure that the costs relating to the change in the seat of EMA will be fully covered by the
Amendment 22 #
Draft legislative resolution Paragraph 3 3.
Amendment 23 #
Draft legislative resolution Paragraph 3 3. Calls on the budgetary authorities and the Commission to ensure that the costs relating to the change in the seat of the EMA will be fully covered by the current host country;
Amendment 24 #
Draft legislative resolution Paragraph 3 a (new) 3 a. Calls upon the UK Government to work with both the Commission and the EMA to ensure all measures are taken to make the transition as smooth as possible; further calls upon them to ensure adequate support is in place for EMA staff throughout the relocation;
Amendment 25 #
Draft legislative resolution Paragraph 4 4. Calls on the budgetary authorities and the Commission to ensure that
Amendment 26 #
Draft legislative resolution Paragraph 4 4. Calls on the budgetary authorities and the Commission to ensure that
Amendment 27 #
Draft legislative resolution Paragraph 4 4.
Amendment 28 #
Draft legislative resolution Paragraph 4 a (new) 4a. Is alarmed by the serious delays that the Dutch Government has already announced, which have pushed back the handover of the Vivaldi building, construction work on which has not yet started, by more than seven months; is concerned about the consequences that the delays will have for the EMA's work, and the resulting need to prioritise some activities over others and repeated changes to its moving schedule to take account of the delays;
Amendment 29 #
Draft legislative resolution Paragraph 4 a (new) 4a. Welcomes the saving to the general budget of the Union resulting from the undertaking by the Dutch Government to shoulder, from January 2018, the additional costs relating to the double transfer of the seat of EMA, first to a temporary location in the Spark Building and then to the Vivaldi Building in Amsterdam;
Amendment 3 #
Draft legislative resolution Paragraph 1 1.
Amendment 30 #
Draft legislative resolution Paragraph 4 a (new) 4a. Considers that the two-stage transfer procedure will prolong the period during which the EMA will be unable to operate to capacity; urges, therefore, that the decision regarding the location of the EMA be reconsidered in the light of the delays occurring in Amsterdam, which are undermining the right to health of our citizens, infringing the principle of continuity and incurring additional costs for the European budget;
Amendment 31 #
Draft legislative resolution Paragraph 5 5.
Amendment 32 #
Draft legislative resolution Paragraph 5 5. Calls on the budgetary authorities and the Commission to ensure that the
Amendment 33 #
Draft legislative resolution Paragraph 5 5. Calls on the budgetary authorities and the Commission to ensure that the
Amendment 34 #
Draft legislative resolution Paragraph 5 5. Calls on the budgetary authorities and the Commission to ensure that the double transfer will not jeopardise the normal operational needs of EMA, and will guarantee business continuity and EMA’s smooth functioning, without disruption, beyond March 2019, including the current work being undertaken to set up the European Portal and Database for Clinical Trials, as required under the Clinical Trials Regulation EU No 536/2014;
Amendment 35 #
Draft legislative resolution Paragraph 5 a (new) 5a. Welcomes the spirit of close cooperation shown by the Dutch Government in responding to the requests of the EEA administration to make the Vivaldi Building available by mid- November 2019 and the fact that EMA meetings can be organised centrally in a provisional location between April and November 2019, as well as the efforts being made by the Dutch authorities to ensure that the double transfer will not jeopardise the operational effectiveness, continuity and uninterrupted functioning of the EMA;
Amendment 36 #
Draft legislative resolution Paragraph 5 a (new) 5 a. To ensure the proper functioning of the European Medicines Agency in its new location, a headquarters agreement should be concluded before the European Medicines Agency takes up its new seat; the building contract should include an 'end of lease' clause which stipulates that should the Member State leave the European Union, the contract is automatically terminated on the exit date; this should become standard practice for all such building leases henceforth, and should also be negotiated into all existing building leases;
Amendment 37 #
Draft legislative resolution Paragraph 5 a (new) 5 a. Calls on the budgetary authorities and the Commission to publish regular reports pertaining to the financial burden incurred as a result of the relocation;
Amendment 38 #
Draft legislative resolution Paragraph 6 a (new) 6a. Calls on the Commission to use the changing of the Agency's seat to review its mandate, tasks and the powers conferred to it, and to immediately begin a dialogue with Parliament on this issue;
Amendment 39 #
Proposal for a regulation Recital 1 (1) In the context of the United Kingdom's notification on 29 March 2017 of its intention to leave the Union, pursuant to Article 50 of the Treaty on European Union, the other 27 Member States, meeting on 20 November 2017 in the margins of the General Affairs Council (‘Article 50’), selected Amsterdam, the Netherlands, as the new seat of the European Medicines Agency. However, the Executive Director was subsequently forced to acknowledge1a that the Amsterdam headquarters would not enable the Agency to become fully operational on schedule. The new seat should therefore be located in Milan (Italy), which was initially unsuccessful purely as a result of a random draw but fully satisfies all the logistic requirements
Amendment 4 #
Draft legislative resolution Paragraph 1 1.
Amendment 40 #
Proposal for a regulation Recital 1 (1) In the context of the United Kingdom's notification on 29 March 2017 of its intention to leave the Union, pursuant to Article 50 of the Treaty on European Union, the other 27 Member States, meeting in the margins of the General Affairs Council (‘Article 50’), selected Amsterdam, the Netherlands, as the new seat of the European Medicines Agency. However, it now emerges that the Amsterdam headquarters will not be ready when the transfer is due to take place and that the provisional location falls short of requirements in terms of space available and the sound administration of public funds; this could detract from the efficiency of the Agency, causing delays in the registration of innovative medicines and advanced life-saving treatments, resulting in enormous harm to European citizens.
Amendment 41 #
Proposal for a regulation Recital 1 a (new) (1a) However, that decision must take into account the need to find a suitable headquarters by March 2019, and no suitable premises are yet available. Furthermore, the building chosen must be immediately fit for purpose to avoid inconvenience, additional costs and repercussions regarding citizens' right to health;
Amendment 42 #
Proposal for a regulation Recital 2 (2) Having regard to Article 50(3) of the Treaty on European Union, the European Medicines Agency should take its new seat
Amendment 43 #
Proposal for a regulation Recital 3 (3) To ensure the proper functioning of the European Medicines Agency in its new location, a headquarters agreement should be concluded
Amendment 44 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a The seat of the Agency shall
Amendment 45 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a The Agency shall have its seat in
Amendment 46 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a The Agency shall have its seat in
Amendment 47 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a The Agency shall have its seat in
Amendment 48 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a The Agency shall have its seat in
Amendment 49 #
Proposal for a regulation Article 1 – paragraph 1 – introductory part In Regulation (EC) No 726/2004, the following Article 71a
Amendment 5 #
Draft legislative resolution Paragraph 1 1. Adopts its position at first reading,
Amendment 50 #
Proposal for a regulation Article 2 – paragraph 2 This Regulation shall apply from
Amendment 51 #
Proposal for a regulation Article 2 – paragraph 2 This Regulation shall apply from
Amendment 6 #
Draft legislative resolution Paragraph 1 a (new) 1a. Reiterates that this Regulation will apply from the date on which the Treaties cease to apply to the United Kingdom or from 30 March 2019, whichever is the earlier.
Amendment 7 #
Draft legislative resolution Paragraph 2 Amendment 8 #
Draft legislative resolution Paragraph 2 2. Regrets that the European Parliament - and ultimately the representatives of the Union’s citizens - were not fully involved in the procedure to select the new seat of the European Medicines Agency (EMA), which was eventually concluded by drawing lots, despite it being such an important decision; decisions in relation to the location of bodies and agencies need, and legally
Amendment 9 #
Draft legislative resolution Paragraph 2 2.
source: 616.891
2018/02/21
AFCO
3 amendments...
Amendment 6 #
Proposal for a regulation Citation 1 a (new) Having regard to the Treaty on European Union, and in particular Article 13(2) thereof,
Amendment 7 #
Proposal for a regulation Recital 1 (1) In the context of the United Kingdom's notification on 29 March 2017 of its intention to leave the Union, pursuant to Article 50 of the Treaty on European Union, the other 27 Member States, meeting in the margins of the General Affairs Council (‘Article 50’), selected Amsterdam, the Netherlands, as the new seat of the European Medicines Agency
Amendment 8 #
Proposal for a regulation Article 1 – paragraph 1 Regulation (EC) No 726/2004 Article 71a – paragraph 1 source: 618.175
|
History
(these mark the time of scraping, not the official date of the change)
docs/4 |
|
docs/5 |
|
docs/7/docs/0/url |
/oeil/spdoc.do?i=30858&j=0&l=en
|
events/7/date |
Old
2018-10-18T00:00:00New
2018-10-17T00:00:00 |
committees/0/shadows/3 |
|
committees/2/rapporteur |
|
docs/0/docs/0/url |
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0004)(documentyear:2018)(documentlanguage:EN)New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:0004)(documentyear:2018)(documentlanguage:EN) |
docs/1/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE615.463New
https://www.europarl.europa.eu/doceo/document/ENVI-PR-615463_EN.html |
docs/2/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE616.891New
https://www.europarl.europa.eu/doceo/document/ENVI-AM-616891_EN.html |
docs/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE616.913&secondRef=02New
https://www.europarl.europa.eu/doceo/document/AFCO-AD-616913_EN.html |
docs/7/docs/0/url |
/oeil/spdoc.do?i=30858&j=0&l=en
|
events/1/type |
Old
Committee referral announced in Parliament, 1st reading/single readingNew
Committee referral announced in Parliament, 1st reading |
events/2/type |
Old
Vote in committee, 1st reading/single readingNew
Vote in committee, 1st reading |
events/3 |
|
events/3 |
|
events/5 |
|
events/5 |
|
events/8 |
|
events/8 |
|
procedure/Modified legal basis |
Rules of Procedure EP 159
|
procedure/Other legal basis |
Rules of Procedure EP 159
|
docs/7/body |
EC
|
events/3/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A8-2018-0063&language=ENNew
http://www.europarl.europa.eu/doceo/document/A-8-2018-0063_EN.html |
events/4 |
|
events/4 |
|
events/4/date |
Old
2018-10-25T00:00:00New
2018-03-15T00:00:00 |
events/5 |
|
events/5/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0086New
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0086_EN.html |
events/7 |
|
events/8/docs/0/url |
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P8-TA-2018-0427New
http://www.europarl.europa.eu/doceo/document/TA-8-2018-0427_EN.html |
committees/0 |
|
committees/0 |
|
committees/2 |
|
committees/2 |
|
committees/5 |
|
committees/5 |
|
activities |
|
commission |
|
committees/0 |
|
committees/0 |
|
committees/1 |
|
committees/1 |
|
committees/2 |
|
committees/2 |
|
committees/3 |
|
committees/3 |
|
committees/4 |
|
committees/4 |
|
committees/5 |
|
committees/5 |
|
council |
|
docs |
|
events |
|
links |
|
other |
|
otherinst |
|
procedure/Mandatory consultation of other institutions |
European Economic and Social Committee European Committee of the Regions
|
procedure/Modified legal basis |
Old
Rules of Procedure EP 150New
Rules of Procedure EP 159 |
procedure/dossier_of_the_committee |
Old
ENVI/8/11697New
|
procedure/final |
|
procedure/instrument |
Old
RegulationNew
|
procedure/other_consulted_institutions |
European Economic and Social Committee European Committee of the Regions
|
procedure/stage_reached |
Old
Awaiting Parliament 1st reading / single reading / budget 1st stageNew
Procedure completed |
procedure/subject |
Old
New
|
procedure/summary |
|
activities/0/commission/0 |
|
activities/0/docs/0/text |
|
activities/1 |
|
activities/2 |
|
activities/3 |
|
activities/4 |
|
committees/0/date |
2018-02-26T00:00:00
|
committees/0/rapporteur |
|
committees/3/date |
2018-01-11T00:00:00
|
committees/3/rapporteur |
|
committees/4/date |
2018-01-10T00:00:00
|
committees/4/rapporteur |
|
committees/4/shadows |
|
other/0 |
|
procedure/Modified legal basis |
Rules of Procedure EP 150
|
procedure/dossier_of_the_committee |
ENVI/8/11697
|
procedure/legal_basis |
|
procedure/stage_reached |
Old
Preparatory phase in ParliamentNew
Awaiting Parliament 1st reading / single reading / budget 1st stage |
activities/0/docs/0/celexid |
CELEX:52017PC0735:EN
|
activities/0/docs/0/celexid |
CELEX:52017PC0735:EN
|
activities |
|
committees |
|
links |
|
other |
|
procedure |
|